Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2017 by Dana-Farber Cancer Institute
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Jacalyn Rosenblatt, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01954979
First received: September 27, 2013
Last updated: February 15, 2017
Last verified: February 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Study Completion Date: No date given
  Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)